Pharmala Biotech Holdings Inc. (MDMA.CN)
CAD 0.16
(-3.03%)
CAD 0.16
(-3.03%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Operating Cash Flow | -339.65 Thousand | -625.37 Thousand | -173.57 Thousand |
| Net Income | -779.81 Thousand | -985.58 Thousand | -2.5 Million |
| Depreciation & Amortization | 52.76 Thousand | 12.13 Thousand | 303.00 |
| Deferred income taxes | 16.86 Thousand | -368.11 Thousand | - |
| Stock-based compensation | 67.72 Thousand | 236.53 Thousand | 142.61 Thousand |
| Change in working capital | 376.86 Thousand | 111.54 Thousand | 109 Thousand |
| Other non-cash items | -74.05 Thousand | 368.11 Thousand | 2.08 Million |
| Investing Cash Flow | -506.73 Thousand | -994.87 Thousand | 629.21 Thousand |
| Investments in PPE | -506.73 Thousand | -994.87 Thousand | -262.18 Thousand |
| Acquisitions | - | - | 891.4 Thousand |
| Investment purchases | - | - | - |
| Sales/Maturities of investments | - | - | - |
| Other Investing Activities | -506.73 Thousand | - | 891.4 Thousand |
| Financing Cash Flow | 189.29 Thousand | - | 2.01 Million |
| Debt repayment | - | - | - |
| Dividends payments | - | - | - |
| Common Stock Repurchased | - | - | - |
| Common Stock Issuance | 189.29 Thousand | - | 83.44 Thousand |
| Other Financing Activities | 189.29 Thousand | - | 1.93 Million |
| Accounts receivables | -114.54 Thousand | -23.21 Thousand | -29.47 Thousand |
| Accounts payables | 214.03 Thousand | - | - |
| Inventory | -5849.00 | -116.34 Thousand | - |
| Other working capital | 283.22 Thousand | 251.1 Thousand | 138.47 Thousand |
| Cash at beginning of period | 852.13 Thousand | 2.47 Million | - |
| Cash at end of period | 195.04 Thousand | 852.13 Thousand | 2.47 Million |
| Capital Expenditure | -506.73 Thousand | -994.87 Thousand | -262.18 Thousand |
| Effect of forex changes on cash | - | - | - |
| Net cash flow / Change in cash | -657.09 Thousand | -1.62 Million | 2.47 Million |
| Free Cash Flow | -846.39 Thousand | -1.62 Million | -435.75 Thousand |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -413.15 Thousand | -222.56 Thousand | 36.47 Thousand | -80.3 Thousand | -779.81 Thousand | -338.74 Thousand |
| Depreciation & Amortization | 15.77 Thousand | 15.77 Thousand | 15.79 Thousand | 13.23 Thousand | 52.76 Thousand | 13.17 Thousand |
| Deferred income taxes | - | - | - | - | 16.86 Thousand | 26.79 Thousand |
| Stock-based compensation | - | 56.59 Thousand | 18.78 Thousand | 5278.00 | 67.72 Thousand | 4450.00 |
| Change in working capital | -195.36 Thousand | 134.01 Thousand | -171.32 Thousand | 87.47 Thousand | 376.86 Thousand | 7555.00 |
| Other non-cash items | 744.38 Thousand | -127.36 Thousand | 114.59 Thousand | -57.19 Thousand | -74.05 Thousand | -26.79 Thousand |
| Investing Cash Flow | -47.44 Thousand | -75.89 Thousand | -56.51 Thousand | -269.43 Thousand | -506.73 Thousand | -72.36 Thousand |
| Investments in PPE | -47.44 Thousand | -75.89 Thousand | -56.51 Thousand | -269.43 Thousand | -506.73 Thousand | -72.36 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 728 Thousand | - | 70 Thousand | - | 189.29 Thousand | 150.19 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 728 Thousand | - | 70 Thousand | - | 189.29 Thousand | 150.19 Thousand |
| Other Financing Activities | - | - | - | - | - | - |
| Accounts receivables | -58.51 Thousand | -19.2 Thousand | 15.12 Thousand | -137.76 Thousand | -114.54 Thousand | 60.82 Thousand |
| Accounts payables | -94.2 Thousand | 144.29 Thousand | 31.09 Thousand | 160.93 Thousand | 214.03 Thousand | - |
| Inventory | -192.47 Thousand | - | 112.03 Thousand | 95.94 Thousand | -5849.00 | -101.78 Thousand |
| Other working capital | 149.83 Thousand | 8918.00 | -329.56 Thousand | -31.64 Thousand | 283.22 Thousand | -53.27 Thousand |
| Cash at beginning of period | 40.34 Thousand | 222.84 Thousand | 195.04 Thousand | 495.99 Thousand | 852.13 Thousand | 731.72 Thousand |
| Cash at end of period | 495.8 Thousand | 40.34 Thousand | 222.84 Thousand | 195.04 Thousand | 195.04 Thousand | 495.99 Thousand |
| Capital Expenditure | -47.44 Thousand | -75.89 Thousand | -56.51 Thousand | -269.43 Thousand | -506.73 Thousand | -72.36 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 455.46 Thousand | -182.5 Thousand | 27.8 Thousand | -300.95 Thousand | -657.09 Thousand | -235.72 Thousand |
| Free Cash Flow | -272.54 Thousand | -182.5 Thousand | -42.19 Thousand | -300.95 Thousand | -846.39 Thousand | -385.92 Thousand |
VALV
SYQH
MNXMF
BGEM
AGFAF
CBL